JP2020524164A - Ｎｋ−９２細胞を用いてメルケル細胞癌（ｍｃｃ）を治療するための方法 - Google Patents

Ｎｋ−９２細胞を用いてメルケル細胞癌（ｍｃｃ）を治療するための方法 Download PDF

Info

Publication number
JP2020524164A
JP2020524164A JP2019570550A JP2019570550A JP2020524164A JP 2020524164 A JP2020524164 A JP 2020524164A JP 2019570550 A JP2019570550 A JP 2019570550A JP 2019570550 A JP2019570550 A JP 2019570550A JP 2020524164 A JP2020524164 A JP 2020524164A
Authority
JP
Japan
Prior art keywords
cells
subject
administered
merkel cell
cell carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019570550A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524164A5 (enExample
Inventor
ハンス クリンゲマン
ハンス クリンゲマン
ティエン リー
ティエン リー
ローラン ボワセル
ローラン ボワセル
Original Assignee
ナントクエスト インコーポレイテッド
ナントクエスト インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナントクエスト インコーポレイテッド, ナントクエスト インコーポレイテッド filed Critical ナントクエスト インコーポレイテッド
Publication of JP2020524164A publication Critical patent/JP2020524164A/ja
Publication of JP2020524164A5 publication Critical patent/JP2020524164A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019570550A 2017-06-20 2018-06-19 Ｎｋ−９２細胞を用いてメルケル細胞癌（ｍｃｃ）を治療するための方法 Pending JP2020524164A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762522335P 2017-06-20 2017-06-20
US62/522,335 2017-06-20
PCT/US2018/038308 WO2018236887A1 (en) 2017-06-20 2018-06-19 Methods for treating merkel cell carcinoma (mcc) using nk-92 cells

Publications (2)

Publication Number Publication Date
JP2020524164A true JP2020524164A (ja) 2020-08-13
JP2020524164A5 JP2020524164A5 (enExample) 2021-07-26

Family

ID=62875317

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019570550A Pending JP2020524164A (ja) 2017-06-20 2018-06-19 Ｎｋ−９２細胞を用いてメルケル細胞癌（ｍｃｃ）を治療するための方法

Country Status (9)

Country Link
US (1) US20200171087A1 (enExample)
EP (1) EP3641790A1 (enExample)
JP (1) JP2020524164A (enExample)
KR (1) KR20200017494A (enExample)
CN (1) CN110753551A (enExample)
AU (1) AU2018288712A1 (enExample)
CA (1) CA3066463A1 (enExample)
IL (1) IL270838A (enExample)
WO (1) WO2018236887A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102476640B1 (ko) 2013-11-01 2022-12-09 이뮤너티바이오, 인크. 종양세포 치사활성 및 항균성 조성물 및 방법
WO2022250312A1 (ko) * 2021-05-27 2022-12-01 (주)에스엠티바이오 신경내분비종양의 치료용 자연살해세포

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7267398A (en) 1997-04-30 1998-11-24 Hans Klingemann Natural killer cell lines and methods of use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HISTORY OF CHANGES FOR STUDY: NCT02465957, JPN6022023354, 23 May 2015 (2015-05-23), ISSN: 0004956910 *
JOURNAL OF IMMUNOTHERAPY OF CANCER, vol. 4, no. 1, JPN6022023352, 2016, pages 35 - 44, ISSN: 0004956909 *
SHAILENDER BHATIA: "ADOPTIVE CELLULAR THERAPY (ACT) WITH ALLOGENEIC ACTIVATED NATURAL KILLER (ANK) CELLS IN PATIENTS WIT", [ONLINE], JPN5020007791, 2016, US, pages 1, ISSN: 0004956908 *
日本臨床, vol. 第71巻,増刊号4, JPN6022023353, 2013, pages 702 - 706, ISSN: 0004956911 *

Also Published As

Publication number Publication date
EP3641790A1 (en) 2020-04-29
KR20200017494A (ko) 2020-02-18
CA3066463A1 (en) 2018-12-27
AU2018288712A1 (en) 2019-12-12
IL270838A (en) 2020-01-30
US20200171087A1 (en) 2020-06-04
WO2018236887A1 (en) 2018-12-27
CN110753551A (zh) 2020-02-04

Similar Documents

Publication Publication Date Title
Li et al. The indoleamine 2, 3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma
Den Otter et al. Local therapy of cancer with free IL-2
US11633380B2 (en) Use of trans-[tetrachlorobis(1H-indazole)ruthenate(III)] for the treatment of cancer
JP2009542623A (ja) Ｈ２遮断薬、少なくとも１つの抗炎症薬剤および細胞毒性薬剤を含む抗がん治療
AU2016328683A1 (en) New therapeutic strategies against blood cancer
CA3113552A1 (en) Immunogenic composition for the treatment of cancer
JP2011506436A (ja) 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
JP2020524164A (ja) Ｎｋ−９２細胞を用いてメルケル細胞癌（ｍｃｃ）を治療するための方法
US20230172984A1 (en) CLEARANCE OF SENESCENT CELLS BY ACTIVATION OF iNKT CELLS
AU2013208649B2 (en) Combination therapy for the treatment of cancer
CN115362253B (zh) 利用维奈托克增强t细胞的方法
JP2020524167A (ja) Ｎｋ−９２細胞とｉｌ−１５アゴニストの併用療法
JP2022512927A (ja) 癌を処置するための組成物および方法
HK40022820A (en) Methods for treating merkel cell carcinoma (mcc) using nk-92 cells
Cayssials et al. Beyond tyrosine kinase inhibitors: Combinations and other agents
HK40021263A (en) Nk-92 cells and il-15 agonist combination therapy
US12472227B2 (en) Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy
KR102558989B1 (ko) 항암 화학요법으로 인한 내성을 완화하고 항암 화학요법의 효과를 증진시키기 위한 약학적 조성물 및 그 용도
Gupta et al. Targeting Bcl-xL to eliminate chemotherapy-induced tumor dormancy and prevent breast cancer metastasis
WO2021062200A1 (en) Enhancing cancer therapy treatment with bh3 mimetics
Khoni Immunotherapy In Malignant Melanoma
Kaffenberger et al. The Therapy of Cutaneous T Cell Lymphoma
US20130338080A1 (en) Compositions and methods for treating an activated b-cell diffuse large b-cell lymphoma
Willemze et al. clinical practice guidelines
WO2019054865A1 (en) T-cell based immunotherapy

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220608

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230105